Sign In
Buy RYTM
$99.25
-6.49 (-6.14%)
At Close: Jul 31, 2026
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress
05:34pm, Tuesday, 25'th Nov 2025
Rhythm Pharmaceuticals, Inc. maintaining a Strong Buy rating, driven by IMCIVREE's growth and multiple late-stage expansion opportunities in rare genetic obesity indications. RYTM's IMCIVREE awaits FD
AXQ Capital LP Purchases Shares of 4,560 Rhythm Pharmaceuticals, Inc. $RYTM
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP purchased a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. T
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
07:00am, Monday, 10'th Nov 2025
– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis o
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million
11:48am, Saturday, 08'th Nov 2025
Rythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, recently exercised and sold some stock options. Shulman still held 8,509 shares directly after the trade.
-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a
AlphaQuest LLC Decreases Stake in Rhythm Pharmaceuticals, Inc. $RYTM
03:37am, Thursday, 06'th Nov 2025
AlphaQuest LLC lowered its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 77.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exch
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript
08:06pm, Tuesday, 04'th Nov 2025
Rhythm Pharmaceuticals, Inc. ( RYTM ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chai
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Tuesday, 04'th Nov 2025
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.73 per share a year ago.
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
07:00am, Tuesday, 04'th Nov 2025
-- Third quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypotha
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:08am, Tuesday, 28'th Oct 2025
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
04:01pm, Tuesday, 21'st Oct 2025
BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Nvidia, These Other AI Plays Lead 5 Stocks Near Buy Points
08:00am, Saturday, 27'th Sep 2025
Three of the five stocks to watch are part of the artificial intelligence trade, including chip company Nvidia.
Rhythm Pharmaceuticals, Inc. - Special Call
05:07pm, Wednesday, 24'th Sep 2025
Rhythm Pharmaceuticals, Inc. - Special Call Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & CEO Jennifer Chien - Execut
2 Under-the-Radar Stocks That Could Soar
10:45am, Sunday, 21'st Sep 2025
While oncology is the largest therapeutic area in the pharmaceutical industry by revenue, the anti-obesity space has grabbed the most attention over the past couple of years. This niche is still in it
